Hämatologische Neoplasien und solide Tumore
- 24 February 2026
- book chapter
- Published by Springer Nature
- p. 83-174
Abstract
No abstract availableKeywords
This publication has 262 references indexed in Scilit:
- Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and EuropeJAMA Oncology, 2021
- Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell CarcinomaJAMA Network Open, 2021
- Evidence Underlying Policy Proposals for Sustainable Anticancer Drug PricesJAMA Oncology, 2020
- Breast Cancer TreatmentJAMA, 2019
- Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug CompaniesJAMA Network Open, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Carfilzomib-Associated Cardiovascular Adverse EventsJAMA Oncology, 2018
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalJAMA Internal Medicine, 2017
- Fulvestrant for hormone-sensitive metastatic breast cancerCochrane Database of Systematic Reviews, 2017
- Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerCochrane Database of Systematic Reviews, 2014